Italia markets close in 4 hours 20 minutes

Prothena Corporation plc (0Y3M.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
23,27+1,06 (+4,77%)
Alla chiusura: 05:53PM BST

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin D02 VK60
Ireland
353 1 236 2500
https://www.prothena.com

Settore/i
Settore
Impiegati a tempo pieno173

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Gene G. Kinney Ph.D.President, CEO & Director1M1,97M1969
Mr. Tran B. Nguyen M.B.A.CFO & Chief Strategy Officer830,14k5,92M1974
Mr. Brandon S. SmithChief Operating Officer757,79k1,07M1975
Ms. Carol D. KarpChief Regulatory Officer701,48k2,1M1953
Dr. Hideki Garren M.D., Ph.D.Chief Medical Officer808,71k1,09M1965
Ms. Karin L. Walker CPAChief Accounting Officer & ControllerN/DN/D1963
Dr. Wagner M. ZagoChief Scientific Officer478,79kN/D1973
Mr. Mark C. Johnson C.F.A.Vice President of Investor RelationsN/DN/DN/D
Mr. Michael J. MalecekChief Legal Officer588,25kN/D1966
Mr. David A. FordChief People OfficerN/DN/D1970
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Prothena Corporation plc al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.